Effect of lactate dehydrogenase and β2-microglobulin levels on the clinical efficacy of first-line chemotherapy regimen for Waldenstr?m Macroglobulinemia
10.13431/j.cnki.immunol.j.20250079
- VernacularTitle:乳酸脱氢酶、β2-微球蛋白水平对华氏巨球蛋白血症一线化疗方案临床效果的影响
- Author:
Xufu HUANG
1
;
Yirong ZHU
1
;
Xuemei WEN
1
;
Zhihong ZHENG
1
Author Information
1. 福建医科大学附属协和医院血液科,福州 350001
- Publication Type:Journal Article
- Keywords:
Waldenstr?m macroglobulinemia;
first-line chemotherapy;
lactate dehydrogenase;
β2-microglobulin;
international prognostic scoring system;
proportion of bone marrow lymphoplasmacytic cells
- From:
Immunological Journal
2025;41(8):551-556
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the effect of serum lactate dehydrogenase(LDH)and β2-microglobulin(β2-MG)on therapeutic efficacy of the first-line chemotherapy regimen for Waldenstr?m Macroglobulinemia(WM).Methods Data were collected from 113 WM patients admitted from March 2019 to February 2024.All patients completed the established first-line chemotherapy regimen and were divided into the response group(n=85)and the non-response group(n=28).The general data between the two groups were compared,with a focus on analyzing the risk factors for non-response to first-line chemotherapy in WM patients and evaluating the predictive value of serum LDH and β2-MG for the efficacy of first-line chemotherapy.Result The non-responsive group had a higher risk of prognosis based on International Prognostic Scoring System(IPSS),a higher rate of MYD88 L265P mutation,higher TP53 deletion/mutation ratio,and higher proportion of bone marrow lymphoplasmacytic cells,as well as higher serum LDH and β2-MG expression than the response group(P＜0.01).Multivariate logistic regression analysis revealed that risk factors for non-response to first-line chemotherapy in WM patients included a high-risk prognosis based on IPSS,an increased proportion of bone marrow lymphoplasmacytic cells,and higher rate of MYD88 L265P mutation and TP53 deletion/mutation,as well as elevated serum LDH and β2-MG levels(P＜0.05).The area under the curve of serum LDH and β2-MG for predicting the risk of non-response to first-line chemotherapy in WM patients was 0.796 and 0.783 respectively.Through interaction analysis,serum LDH and β2-MG had a positive interaction effect on non-response to chemotherapy in WM patients.Conclusion The non-response to first-line chemotherapy in WM patients is related to abnormal increase in serum LDH and β2-MG.Pre-chemotherapy detection of LDH and β2-MG level has certain predictive value for the risk of non-response to chemotherapy,and the simultaneous increase of both may lead to a higher risk of non-response to chemotherapy.
